The Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) is a federally chartered advisory committee established January 9, 2002, in response to the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Authorization Act of 2000 (42 U.S.C. 285l-3(d)). SACATM advises ICCVAM, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), and the director of NIEHS and NTP regarding statutorily mandated duties of ICCVAM and activities of NICEATM. SACATM provides advice on priorities and activities related to the development, validation, scientific review, regulatory acceptance, implementation, and national and international harmonization of new, revised, and alternative toxicological test methods. The SACATM charter and current roster are available on the NTP website. The table below provides the roster for FY 2016. SACATM typically meets once a year and members serve rotating terms of up to four years. Lori White, Ph.D., served as the designated federal officer and manager of SACATM.
SACATM met once during FY 2016 on September 27, 2016, at NIEHS. At the meeting, ICCVAM and NICEATM updated SACATM on the activities since the last meeting. The focus of the meeting was a strategy for implementing the vision for regulatory toxicity testing in the 21st century. SACATM was updated on ICCVAM’s strategy for the six most commonly used acute animal tests and their roadmap for skin sensitization testing. Additional presentations included (1) moving away from animal models for toxicity testing, (2) impediments to adoption of alternative approaches, (3) coordinating activities between the federal government and stakeholders, (4) promoting adoption of alternative testing strategies, and (5) the next steps toward developing a strategy for implementing the vision for toxicity testing in the 21st century.
Members of SACATM, ICCVAM, and staff from NIEHS and NTP at the September 2016 SACATM meeting
Name and Title | Affiliation | Term End Date |
---|---|---|
Brian Berridge, D.V.M., Ph.D., D.A.C.V.P. Director, WW Animal Research Strategy |
GlaxoSmithKline King of Prussia, Pennsylvania |
11/30/19 |
Lauren E. Black, Ph.D. Senior Scientific Advisor Navigators Services |
Charles River Laboratories Reno, Nevada |
11/30/16 |
Tracie E. Bunton, D.V.M., Ph.D. Consultant |
Eicarte LLC Gettysburg, Pennsylvania |
11/30/15 |
Joan M. Chapdelaine, Ph.D. Senior Immunologist and Director, Business Development |
Calvert Laboratories, Inc. Scott Township, Pennsylvania |
11/30/15 |
Mark G. Evans, D.V.M., Ph.D., A.C.V.P. Research Fellow La Jolla Laboratories |
Pfizer San Diego, California |
11/30/15 |
Hisham Hamadeh, Ph.D., D.A.B.T., M.B.A. Director, Comparative Biology and Safey Sciences |
Amgen, Inc. Thousand Oaks, California |
11/30/19 |
William P. Janzen (Chair) Executive Director of Lead Discovery |
Epizyme, Inc. Cambridge, Massachusetts |
6/30/17 |
Safdar A. Khan, D.V.M., M.S., Ph.D., D.A.B.V.T. Associate Director Global Pharmacoavigilance |
Zoetis Kalamazoo, Michigan |
11/30/16 |
Lawrence Milchak, Ph.D., D.A.B.T. Senior Manager, Toxicology and Strategic Services |
3M St. Paul, Minnesota |
11/30/19 |
Pamela J. Spencer, Ph.D., D.A.B.T. Director of Regulatory and Product Stewardship |
ANGUS Chemical Company Buffalo Grove, Illinois |
11/30/19 |
Catherine E. Willett, Ph.D. Director Regulatory Toxicology, Risk Assessment and Alternatives |
The Humane Society of the United States Gaithersburg, Maryland |
11/30/17 |
Wei Xu, Ph.D. Associate Professor Department of Oncology McArdle Laboratory for Cancer Research |
University of Wisconsin at Madison Madison, Wisconsin |
11/30/17 |
Hao Zhu, Ph.D. Assistant Professor Department of Chemistry |
Rutgers University at Camden Camden, New Jersey |
11/30/19 |